In Valeant Pharmaceuticals v. Mylan Pharmaceuticals, the Federal Circuit clarified venue for Hatch-Waxman cases by holding that infringement only occurs where the ANDA filer took actions related to its ANDA submission, thereby resolving a split among district courts post-TC Heartland. This webinar will address the impact of Valeant on Hatch-Waxman litigation, including how it affects where cases can be filed and litigated. The webinar will also explain how litigants can use multi-district litigation to consolidate pre-trial proceedings in Hatch-Waxman cases, and discuss common issues that arise in multi-district patent litigation.